Batch Fermentation and Microbiome Analysis
Evaluation of the Effect of Different Nutrients on the Gut Microbiota Composition and Metabolic Activity by Using in Vitro Batch Fermentation and Cellular Models
1 other identifier
observational
40
1 country
1
Brief Summary
The correlation between diet and microbiota as well as the effect of microbiota on human health is well established. Studies have shown that people following specific diets have different microbiome profile compared to those following traditional or ordinary diets. In order to screen several food ingredients for their effects on human microbiota composition and metabolic activities, in vitro studies are proposed. Nutrients are added in-vitro in fecal sample, eliminating the need for participants to consume any nutritional product. The batch fermentation in vitro system simulates human colonic microbiota from fecal samples, enabling the complex mixture of microorganisms. This system could serve as a simple model to simulate the diversity as well as the metabolism of human colonic microbiota. We will evaluate the effect on nutrient/s on the age specific microbiome via an in vitro fermentation approach for the 0 to 60 year-old period.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Aug 2020
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
August 18, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 25, 2020
CompletedFirst Submitted
Initial submission to the registry
March 16, 2023
CompletedFirst Posted
Study publicly available on registry
October 24, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
March 26, 2025
CompletedDecember 18, 2025
December 1, 2025
7 days
March 16, 2023
December 11, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Change in microbiota composition
Measured by 16s rRNA sequencing or next Generation Sequencing (NGS) or by qPCR
Through study completion, an average of 1 year
Secondary Outcomes (3)
Change in Short Chain Fatty Acids (SCFA)
Through study completion, an average of 1 year
Change in metabolic profile
Through study completion, an average of 1 year
Protein expression of epithelial cells
Through study completion, an average of 1 year
Eligibility Criteria
Healthy population
You may qualify if:
- Healthy participant aged from 0 to 60 (based on medical history, physical examination and review of childhood growth chart)
- Written informed consent has been obtained from the parent(s)/legally acceptable representative (LAR) of toddlers and teenagers
- Written informed consent has been obtained for participants aged from 14 years old and above
- Child's parent(s)/legal representative or participant is willing and able to fulfill the requirements of the study protocol.
- Ability to collect their or their infant/child's fecal sample.
You may not qualify if:
- The parent(s)/legally acceptable representative (LAR) is not able to provide evidence of parental authority or legal representation.
- Participant following a particular regimen of any type such as vegan, vegetarian, ketogenic, paleo diet,
- Chronic or recurrent diarrhea with spontaneous bowel movements more often than 2 times daily,
- Antibacterial/antifungal therapy during the 3 months prior to study enrolment,
- Medications or supplements that are known to alter gut function or microbiota (i.e. acid antisecretory drugs, pre-/probiotics supplements, laxatives) during the 4 weeks prior to study enrolment,
- Prior gastrointestinal surgery (apart from appendectomy, cholecystectomy or herniotomy),
- Alcohol intake higher than 2 servings per day. A serving is 0.4 dl of strong alcohols, 1 dl of red or white wine, or 3 dl of beer,
- Artificially sweetened beverage intake higher than 1000 ml/ per day,
- Current or history of gastrointestinal diseases like (Celiac Disease, Crohn's Disease, Ulcerative colitis, Irritable Bowel Syndrome, infantile colic, recurrent abdominal pain, functional constipation, ulcers, infections (based on anamnesis),
- Participants participating in another interventional study,
- Participants/parents having a hierarchical or family link with the research team members.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Nestle Clinical Innovation Lab
Lausanne, Canton of Vaud, 1000, Switzerland
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- OTHER
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
March 16, 2023
First Posted
October 24, 2023
Study Start
August 18, 2020
Primary Completion
August 25, 2020
Study Completion
March 26, 2025
Last Updated
December 18, 2025
Record last verified: 2025-12
Data Sharing
- IPD Sharing
- Will not share